JP2009523724A5 - - Google Patents

Download PDF

Info

Publication number
JP2009523724A5
JP2009523724A5 JP2008550323A JP2008550323A JP2009523724A5 JP 2009523724 A5 JP2009523724 A5 JP 2009523724A5 JP 2008550323 A JP2008550323 A JP 2008550323A JP 2008550323 A JP2008550323 A JP 2008550323A JP 2009523724 A5 JP2009523724 A5 JP 2009523724A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
compound according
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008550323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009523724A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/049489 external-priority patent/WO2007087068A2/en
Publication of JP2009523724A publication Critical patent/JP2009523724A/ja
Publication of JP2009523724A5 publication Critical patent/JP2009523724A5/ja
Pending legal-status Critical Current

Links

JP2008550323A 2006-01-13 2006-12-28 チロシンキナーゼ阻害剤およびその使用方法 Pending JP2009523724A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75861706P 2006-01-13 2006-01-13
PCT/US2006/049489 WO2007087068A2 (en) 2006-01-13 2006-12-28 Inhibitors of tyrosine kinases and uses thereof

Publications (2)

Publication Number Publication Date
JP2009523724A JP2009523724A (ja) 2009-06-25
JP2009523724A5 true JP2009523724A5 (https=) 2010-02-18

Family

ID=38309713

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008550323A Pending JP2009523724A (ja) 2006-01-13 2006-12-28 チロシンキナーゼ阻害剤およびその使用方法

Country Status (12)

Country Link
US (5) US7625880B2 (https=)
EP (1) EP1981888A4 (https=)
JP (1) JP2009523724A (https=)
KR (1) KR20080098490A (https=)
CN (1) CN101421269A (https=)
AU (1) AU2006336506B2 (https=)
BR (1) BRPI0621027A2 (https=)
CA (1) CA2636696A1 (https=)
IL (1) IL192640A0 (https=)
MX (1) MX2008008642A (https=)
RU (1) RU2008133161A (https=)
WO (1) WO2007087068A2 (https=)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080098490A (ko) * 2006-01-13 2008-11-10 파마시클릭스, 인코포레이티드 티로신 키나제 억제제 및 이의 용도
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
US7786159B2 (en) 2006-12-01 2010-08-31 Stategics, Inc. Thrombopoietin mimetics
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
IL295053A (en) * 2007-03-28 2022-09-01 Pharmacyclics Llc Broton tyrosine kinase inhibitors
ES2660418T3 (es) 2008-07-16 2018-03-22 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
SG177451A1 (en) * 2009-07-02 2012-02-28 Newgen Therapeutics Inc Phosphorus containing quinazoline compounds and methods of use
JP2013521318A (ja) * 2010-03-08 2013-06-10 ラティオファルム ゲー・エム・ベー・ハー ダビガトランエテキシラートを含有する医薬組成物
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
EA025496B1 (ru) 2011-05-17 2016-12-30 Принсипиа Биофарма Инк. Ингибиторы тирозинкиназы
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
US9138436B2 (en) 2011-07-13 2015-09-22 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
EP2734205B1 (en) 2011-07-21 2018-03-21 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US9365566B2 (en) 2012-03-27 2016-06-14 Takeda Pharmaceutical Company Limited Cinnoline derivatives
US20150166591A1 (en) * 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
JO3754B1 (ar) 2012-06-04 2021-01-31 Pharmacyclics Llc أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
KR101458272B1 (ko) * 2012-08-01 2014-11-07 공주대학교 산학협력단 레티노이드 및 C-Jun N-말단 억제제를 포함하는 암세포 성장 억제제
ME03455B (me) 2012-09-10 2020-01-20 Principia Biopharma Inc Jedinjenja pirazolopirimidina kao inhibitori kinaze
EA201590855A1 (ru) 2012-11-15 2015-11-30 Фармасайкликс, Инк. Соединения пирролопиримидина как ингибиторы киназ
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
MX394360B (es) 2013-03-14 2025-03-24 Sumitomo Pharma Oncology Inc Inhibidores de jak2 y alk2 y metodos para su uso.
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
HRP20170217T1 (hr) 2013-04-25 2017-04-21 Beigene, Ltd. Fuzinirani heterociklički spojevi kao inhibitori protein kinaze
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
CA2919996A1 (en) 2013-08-02 2015-02-05 Pharmacyclics Llc Methods for the treatment of solid tumors
US9415050B2 (en) 2013-08-12 2016-08-16 Pharmacyclics Llc Methods for the treatment of HER2 amplified cancer
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
CN106170297A (zh) * 2013-09-20 2016-11-30 纪念斯隆-凯特琳癌症中心 用于wt‑1‑阳性疾病的组合/辅助疗法
CA2925124A1 (en) 2013-09-30 2015-04-02 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US9795604B2 (en) 2013-10-25 2017-10-24 Pharmacyclics Llc Methods of treating and preventing graft versus host disease
TW202402295A (zh) * 2013-12-02 2024-01-16 美商製藥公司 治療及預防異體抗體所驅動之慢性移植體對抗宿主疾病之方法
PT3107544T (pt) 2014-02-21 2021-01-05 Principia Biopharma Inc Sais e forma sólida de um inibidor de btk
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
AU2015296215A1 (en) 2014-08-01 2017-03-23 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
SG11201700849XA (en) 2014-08-07 2017-03-30 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
US10485797B2 (en) 2014-12-18 2019-11-26 Principia Biopharma Inc. Treatment of pemphigus
WO2016120746A1 (en) * 2015-01-29 2016-08-04 Micro Labs Limited A pharmaceutical composition comprising roflumilast
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
CN104945433B (zh) * 2015-06-24 2017-03-22 苏州大学张家港工业技术研究院 一种制备环丙基膦酸酯的方法
TW201718572A (zh) 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
CN107021963A (zh) 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
CA3019134C (en) 2016-03-31 2024-04-23 Takeda Pharmaceutical Company Limited Isoquinolinyl triazolone complexes
MA45547A (fr) 2016-06-29 2019-05-08 Principia Biopharma Inc Formulations à libération modifiée à base de 2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétane-3-yl)pipérazine-1-yl]pent-2-ènenitrile
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
CA3033827A1 (en) 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl )-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide,preparation, and uses thereof
PT3500299T (pt) 2016-08-19 2024-02-21 Beigene Switzerland Gmbh Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
CN109982687A (zh) 2016-09-19 2019-07-05 梅制药公司 联合疗法
EP3573989A4 (en) 2017-01-25 2020-11-18 Beigene, Ltd. CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
TW202515616A (zh) 2017-06-26 2025-04-16 英屬開曼群島商百濟神州有限公司 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
WO2019034009A1 (en) 2017-08-12 2019-02-21 Beigene, Ltd. BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
CN112533602A (zh) 2018-04-05 2021-03-19 大日本住友制药肿瘤公司 Axl激酶抑制剂及其用途
CN117838695A (zh) 2018-04-13 2024-04-09 住友制药肿瘤公司 用于治疗骨髓增殖性肿瘤和与癌症相关的纤维化的pim激酶抑制剂
MX2021000977A (es) 2018-07-26 2021-04-12 Sumitomo Pharma Oncology Inc Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
NZ778055A (en) 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
WO2020249001A1 (zh) 2019-06-10 2020-12-17 百济神州瑞士有限责任公司 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
TWI877239B (zh) 2019-10-14 2025-03-21 美商普林斯匹亞生物製藥公司 藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈來治療免疫血小板減少症之方法
CN110713497A (zh) * 2019-10-30 2020-01-21 成都海杰亚医药科技有限公司 一种Brigatinib的中间体2-氨基苯基二甲基氧化膦制备方法
JP2023511105A (ja) 2020-01-22 2023-03-16 プリンシピア バイオファーマ インコーポレイテッド 2-[3-[4-アミノ-3-(2-フルオロ-4-フェノキシ-フェニル)-1h-ピラゾロ[3,4-d]ピリミジン-1-イル]ピペリジン-1-カルボニル]-4-メチル-4-[4-(オキセタン-3-イル)ピペラジン-1-イル]ペンタ-2-エンニトリルの結晶形態
CN116332818B (zh) * 2021-12-22 2023-12-15 王喆明 四氢吡咯衍生物及其应用
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder
EP4611753A1 (en) 2022-10-31 2025-09-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326469B1 (en) * 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
US6303652B1 (en) * 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
CA2385747A1 (en) 1999-09-17 2001-03-22 Gavin C. Hirst Pyrazolopyrimidines as therapeutic agents
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US6506769B2 (en) * 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
EP1222187B1 (en) 1999-10-06 2004-09-22 Boehringer Ingelheim Pharmaceuticals Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
EP1235567A2 (en) 1999-11-30 2002-09-04 Parker Hughes Institute Inhibitors of collagen-induced platelet aggregation
AU2439701A (en) 1999-12-17 2001-06-25 Ariad Pharmaceuticals, Inc. Novel heterocycles
GB0005345D0 (en) * 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
HUP0303656A3 (en) * 2000-10-23 2006-03-28 Bristol Myers Squibb Co Modulators of bruton's tyrosine kinase, their identification and use
AU2002315389A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
WO2003016338A1 (en) * 2001-08-15 2003-02-27 Parker Hughes Institute Crystal structure of the btk kinase domain
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2004100868A2 (en) * 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
US7405295B2 (en) * 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) * 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
US7855214B2 (en) * 2004-01-26 2010-12-21 Vertex Pharmaceuticals Incorporated Fused cyclic systems useful as inhibitors of TEC family protein kinases
KR20080098490A (ko) * 2006-01-13 2008-11-10 파마시클릭스, 인코포레이티드 티로신 키나제 억제제 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2009523724A5 (https=)
JP2009504764A5 (https=)
JP2021534124A5 (https=)
JP2006524660A5 (https=)
JP2006517591A5 (https=)
JP2015512860A5 (https=)
JP2020532547A5 (https=)
JP2019529484A5 (https=)
JP2018530549A5 (https=)
JP2016526558A5 (https=)
JP2010511626A5 (https=)
JP2010077141A5 (https=)
JP2008508303A5 (https=)
JP2020529994A5 (https=)
JP2009535307A5 (https=)
JP2003306481A5 (https=)
JP2020512337A5 (https=)
JP2015531789A5 (https=)
JP2017526716A5 (https=)
RU2008133161A (ru) Ингибиторы тирозин киназ и их применение
JP2004517099A5 (https=)
JP2011507878A5 (https=)
JP2009502801A5 (https=)
JP2020507589A5 (https=)
JP2020500866A5 (https=)